Amazon just paid Synopsys over $1 billion to design its own chips — long SNPS on the dip
A billion-dollar-plus licensing deal is real, recurring revenue for Synopsys and confirms that cloud giants are racing to design custom chips — work that flows straight through Synopsys's software. Unlike AI hype stories, this is a signed contract, not a promise. Big cloud custom-chip programs are a multi-year trend, giving Synopsys a durable growth lane that the market can reward steadily.
Idea
A billion-dollar-plus licensing deal is real, recurring revenue for Synopsys and confirms that cloud giants are racing to design custom chips — work that flows straight through Synopsys's software. Unlike AI hype stories, this is a signed contract, not a promise. Big cloud custom-chip programs are a multi-year trend, giving Synopsys a durable growth lane that the market can reward steadily.
Advanced Analysis — institutional-depth research report
Verdict: A Signed $1B+ AWS Deal Is Real, But the Trade Isn't Live Yet
The thesis has one genuinely strong leg: per Reuters (September 30, 2026), Synopsys and AWS signed a chip-design licensing deal worth more than $1 billion — a signed contract landing on a business whose quarter ended July 31, 2026 showed revenue of $2.48B (+8.8% quarter over quarter), net income rebounding to $545.8M, and free cash flow of $746M (+29.9%). The strongest argument against is that the filings don't yet corroborate the story: the June 30, 2026 ownership window shows net open-market insider selling of roughly $15.8M at Synopsys and $42.9M at Amazon, Synopsys's gross margin has slid from a 79–82% historical range to about 72.6%, and the reported pay and dilution picture is unhelpful — shares outstanding rose from 155.1M in April 2025 to 191.6M by July 2026, about 24% in a year. On the trade itself, nothing is live: Synopsys closed at $419.39, $10.07 above its Bollinger (20) midpoint of $409.32, and RSI (14) at 55.9 sits 15.9 points above the 40 entry threshold, while Amazon's RSI at 51.3 is 11.3 points above. The only completed evaluation is a nine-month window with just four trades, a 50% win rate, a 3.2% return and a 5.4% maximum drawdown — too small a sample to lean on, and no robust parameter setup was established. Wait for either the entry conditions to trigger on a pullback or the next Synopsys quarterly report to show the licensing revenue actually landing in the P&L.
Trade now
**Nothing is live yet — this is a wait, not a chase.** Synopsys closed at $419.39, which is $10.07 *above* its Bollinger (20) midpoint of $409.32, so the first entry condition (price below that midpoint) is not met. Three of four conditions are close or satisfied on SNPS: the stochastic crossover is in place, trend strength (ADX of 18.1) is comfortably below the 30 ceiling, but RSI (14) at 55.9 is well above 40 and would need to roll back below and cross up through 40 to qualify. On Amazon, price is already below its midpoint ($251.80 versus $252.44) and ADX at 9.7 passes easily — the binding constraint is again RSI at 51.3, still 11.3 points above the 40 threshold. Waiting concretely means: a pullback that drags RSI toward 40 while price sits under the midpoint, with trend strength staying below 30. **The risk math is defined in advance.** Once triggered, the strategy sizes each position at fixed risk (2.34% of the account per trade, positions capped at 25% each), cuts losers at a 2.3% unrealized loss, and takes profits at a 4.7% gain — a built-in reward-to-risk of roughly 2:1. Additional exits fire if RSI rises above 65, price closes back under the midpoint after entry, or a position ages past 90 trading days. **What the evidence says about this exact setup.** In the completed nine-month evaluation the strategy traded four times on SNPS and returned 3.2% with a 50% win rate and a maximum drawdown of 5.4%. That is a modest, controlled profile — consistent with a mean-reversion entry that needs volatility to calm down first, which is exactly what the ADX-below-30 condition enforces. Note that fill fidelity in that evaluation was coarse (exits filled on daily bars, not intrabar), so treat the drawdown figure as approximate. **One parameter caveat.** No robust alternative parameter setup was established for this strategy — the frozen configuration is what you get, and per the research author's decision no optimization variants were applied. Trade the rules as published or not at all.
A signed contract, not a promise: the numbers behind the Synopsys-Amazon licensing thesis
The thesis rests on a concrete event, not a narrative: per Reuters (September 30, 2026), Synopsys and Amazon Web Services signed a chip-design licensing deal worth more than $1 billion. That is exactly the kind of signed, recurring revenue the idea argues separates this from AI hype — and it lands on top of a Synopsys business that is already growing fast. Synopsys's fiscal Q4 2025 revenue of $2.25B grew 37.8% year over year, placing it in the 86th percentile among 897 information technology peers, with free cash flow in the 94th percentile of its sector. The most recent quarters show the fundamental engine re-accelerating. In the quarter ended July 31, 2026, Synopsys revenue rose 8.8% sequentially to $2.48B, net income jumped from $17.1M to $545.8M, net margin recovered from 0.75% to 22.0%, and operating margin climbed 9.1 percentage points to 14.4%. Free cash flow of $746M was up 29.9% from the prior quarter. If the AWS deal's licensing revenue layers onto that trajectory, the bull case gets a multi-year, contracted growth lane rather than a one-off pop. Amazon's side of the trade is also consistent with the thesis. Custom-silicon investment shows up in Amazon's capex — $39.5B in the quarter ended December 31, 2025 — and Amazon still generated $54.5B of operating cash flow that quarter, the top free-cash-flow result among 575 consumer discretionary peers, with an operating margin in the 83rd percentile. A customer that can fund an aggressive chip program at this scale is precisely the durable counterparty the idea requires.…
Scores
- Conviction score breakdown: 49
- Thesis support: 62
- Trade readiness: 40
- Risk quality: 55
- Backtest evidence: 30
- Fundamentals trend: 58
Watch items
- SNPS — RSI (14)
- SNPS — Price vs Bollinger (20) midpoint
- SNPS — ADX (14)
- AMZN — RSI (14)
- AMZN — Insider net open-market selling
- SNPS — Insider net open-market selling
- SNPS — Quarterly revenue
- SNPS — RSI (14)